INTRODUCTION
Most nucleoside-derived drugs currently used in the treatment of hematological malignancies are purine analogues. These compounds may directly repress DNA replication and interfere with the endogenous nucleotide metabolism, by inhibiting key enzymes like ribonucleotide reductase, thus promoting the incorporation of phosphorylated drugs into DNA. Nucleoside-derived drugs may also exert their cytotoxic action in a non-cycledependent manner since they are equally effective in the treatment of B-cell chronic lymphocytic leukemia (CLL) . 1 This disease is characterized by the accumulation of longlived, functionally inactive, mature appearing, neoplastic B lymphocytes. 2 The clonal excess of B-cells is mainly caused by a decrease in cell death rather than by increased cell proliferation. 3 Although no curative treatment is currently available for CLL patients, several drugs, such as purine nucleoside analog fludarabine, have shown high activity against the disease 4 and evidence indicates that in CLL cells these drugs exert their cytotoxic effect by promoting apoptosis. [5] [6] [7] [8] Although nucleoside metabolism appears to be a necessary step in the development of cytotoxicity the major routes of nucleoside uptake in CLL patients have not been studied at the molecular level. With the molecular cloning of concentrative, high-affinity, and equilibrative, low-affinity nucleoside transporters (CNTs and ENTs, respectively) 9-12 a new panel of putative proteins determining nucleoside-derived drug bioavailability and pharmacological action is now available for analysis in lymphoproliferative malignancies and other types of cancer.
Three isoforms of CNT transporters have been identified up to now. [9] [10] [11] [12] CNT1, which is a pyrimidine nucleoside preferring-transporter, CNT2, a purine-nucleoside preferringcarrier protein, and the recently cloned CNT3, a broad-specificity nucleoside transporter protein. Two equilibrative nucleoside transporters differing in their sensitivity to the nucleoside analog NBTI have been kinetically defined. [10] [11] [12] [13] NBTI-sensitive and insensitive transport systems correspond to ENT1 and ENT2. Nucleoside transport processes across the plasma membrane are not constitutive. 14 Neither is the pattern of isoform expression among different cell types and tissues. 14, 15 Selective loss of nucleoside isoform transporter expression has been reported in animal cancer models, 16, 17 and very recently in human only.
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Immune system cells and cells derived from selected lymphoproliferative malignancies are unique in their ability to relate nucleoside transporter gene expression with transporter biological function in intact cells. The panel of nucleoside transporters expressed in immune system cells has been determined in our laboratory. Both, concentrative and equilibrative transport systems were functionally detected in the human B-cell lines Raji and BLS. 19, 20 In these studies it was found that they were equally sensitive to cytokine treatment and cell activation. CNT1 and CNT2 transporter expression were also up-regulated after induction of bone marrow murine macrophage apoptosis by LPS or TNF-alpha treatments, whereas the equilibrative transporter isoform ENT1 appeared to respond to cell proliferation induced by MCSF. 21, 22 Recently, Dumontet and coworkers analyzed the potential mechanisms of resistance to cytarabine in acute myeloid leukemia (AML) patients by measuring different relevant genes, including hENT1, by RT-PCR. 23 Although these authors showed that reduced hENT1 mRNA in leukemic blasts at diagnosis may correlate with clinical outcome, at present there is no comprehensive study involving all the nucleoside transporter genes cloned so far (CNT1, CNT2, CNT3, ENT1 and ENT2) that aims to identify the role of nucleoside transport processes in nucleoside-derived drug cytotoxicity in CLL.
The aim of this study was to analyze the expression of these nucleoside transporters cloned so far in hematologic cell lines and CLL cells and to study whether transport of fludarabine into cells could explain the sensitivity of these cells to fludarabine-induced cytotoxicity.
only.
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MATERIALS AND METHODS

Patients.
Twenty-two patients (12 men and 10 women) with a median age of 69 years ( range 41 to 91) diagnosed with CLL and who had not been previously treated with fludarabine were included in the study. The diagnosis was established according to the World Health Organization classification. 24 All patients were informed of the nature of this study and informed consent was obtained from each patient in accordance with Hospital Clinic Ethical
Committee.
Cell lines
The following human cell lines were used: Raji, and Daudi derived from a Burkitt lymphoma, Jurkat derived from a immature T-cell leukemia, Granta 519 and NCEB derived from mantle cell lymphoma, JVM-2 derived from a B-cell prolymphocytic leukemia, DOHH2 derived from a follicular lymphoma, NB4 derived from a promyelocytic leukemia and Sw480 derived from colon adenocarcinoma. Cell lines were purchased from the American Type Culture Collection (ATCC), except for Granta 519, NCEB and JVM-2 that were a generous gift of Dr N Andersen (Copenhagen, Denmark).
Reagents.
Fludarabine monophosphate was obtained from Schering AG (Berlin, Germany).
[ transcriptase and random hexamers) were used, as described by the manufacturer (Applied Biosystems, Foster City, CA) . The primers and probes used to amplify nucleoside transporters cDNA by real time PCR were designed using Primer Express software and are listed in Table 1 . Real time monitoring of PCR amplification of cDNAs was done using the Taqman Universal master mix (Applied Biosystems) using 200 nM of probe and 100 nM of each primer, in the ABI Prism 7700 sequence Detection System (Applied Biosystems).
Relative quantification of gene expression was performed as described in the Taqman user's manual using human β-glucoronidase (GUSB) (Applied Biosystems) as an internal control.
The threshold cycle (C T ) is defined as the cycle number at which the fluorescence corresponding to the amplified PCR product is detected. The PCR arbitrary units of each transporter was defined as the mRNA levels of these genes normalized to the GUS expression level in each case. RNA from JVM-2 cell line was used as reference control to normalize each nucleoside transporter/GUS amplification ratios.
Nucleoside uptake measurements in JVM-2 cells and CLL-cells from patients
Nucleoside uptake was measured using a rapid filtration method adapted from a technique previously characterized at our laboratory. 26 Cells were washed and resuspended 
Cell viability assay.
Cell viability was determined by the MTT assay as previously described 27 . CLL Table 2 normalized C T values have been substituted by symbols to reflect the extent of gene expression for every single nucleoside transporter gene. Positive symbols in a scale from one to three reflect increasing expression levels, as indicated in the legend to Table 2. CNT1, the high-affinity nucleoside transporter involved in fluoropyrimidine uptake, is not expressed in normal human leukocytes and human leukemic cell lines. A colon-derived cell line (SW480) and human kidney cDNA were used as positive controls, showing that the lack of expression of CNT1 is not the result of impaired amplification reaction. CNT2 was broadly expressed in all analyzed cells, whereas CNT3 had a low expression in three out of eight leukemic cell lines studied, and it was detected at low levels in normal leukocytes. In contrast, ENT transporters were expressed in all cases and no great variability among cells and cell lines in mRNA levels was observed. Figure 1 shows the amount of ENT1, ENT2, CNT2 and CNT3 mRNAs in CLL cells from 22 patients. The expression of each nucleoside transporter in JVM-2 cells was used as a relative calibrator and the expression levels of these cells were assigned the value of 1 as an arbitrary unit. No CNT1 expression was observed in any of CLL patients analyzed even when the number of amplification cycles was increased to 50, in agreement with the observations in most normal human leukocytes and leukemic cell lines (Table 2 ).
CNT and ENT mRNA expression levels in CLL patients
Significant heterogeneity among patients was observed in ENT1, ENT2, CNT2 and CNT3 mRNA levels. Indeed, the expression pattern of the four studied genes for every only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From patient did not result in any significant partition into subgroups when a cluster analysis was performed (not shown). When every transporter gene was considered individually, the highest variability was found for the CNT3 carrier, whereas the isoform showing least heterogeneity in the population was ENT2. Extensive correlation analysis was performed to assess a possible relationship between these genes at the mRNA level but no correlation was found (data not shown).
Characterization of nucleoside transport into JVM-2 cells
A basic characterization of the transport processes involved in nucleoside uptake into the model cell line JVM-2 was performed. Uridine was initially chosen as a substrate for two reasons: first, it is broadly recognized by all cloned human nucleoside transporters, and, second, it is poorly metabolized. Uridine uptake into JVM-2 cells was clearly linear for up to 10 minutes whereas a significant fraction of this transport activity appeared to be Nadependent, according to the differences found in uridine accumulation measured either in a sodium chloride or a choline chloride medium (Figure 2A ). Some pyrimidine and purine nucleosides, such as cytidine and guanosine, appear to be transported independently by the pyrimidine-preferring and purine-preferring nucleoside carriers, CNT1 and CNT2 respectively. In principle, both may be substrates for the recently cloned isoform CNT3. To determine which specific nucleoside transporter isoforms would account for the uridine transport activity detected in JVM-2 cells, further experiments were performed using guanosine and cytidine as substrates. Uptake of both nucleosides was linear for several minutes (not shown) and was also partially Na-dependent, although a significant component of nucleoside transport into JVM-2 cells appeared to be equilibrative ( Figures 2B and 2D ).
The NBTI-sensitive and -insensitive carriers ENT1 and ENT2 appear to be responsible for this uptake activity, in agreement with the pattern of mRNA expression detected in this cell line (see Table 2 ). Since the pyrimidine-preferring transporter CNT1 was not detected in JVM-2 cells in terms of mRNA, cytidine uptake may be the result of CNT3 expression. In that case, pyrimidine (cytidine) transport would be cross-inhibited by a purine nucleoside, such as guanosine. As shown in Figure 2E , 100µM guanosine completely blocked Nadependent cytidine uptake, which strongly indicates that pyrimidine nucleoside in JVM-2 (Table 2) .
Fludarabine uptake into JVM-2 cells
The same method referred above was used to monitor fludarabine transport into JVM-2 cells. Interestingly, this cell line showed a much higher capacity to accumulate fludarabine than natural nucleosides. In fact, transport processes were extremely rapid, and thus linear velocity conditions were lost before the first minute of incubation ( Figure 3A ).
Although this feature would compromise conventional determinations of substrate uptake kinetics, fludarabine accumulation into JVM-2 cells could be measured reliably at short incubation times-points (i.e. 5s) and reflects, as for the natural substrates, the pattern of gene expression found for JVM-2 cells shown in Table 2 . As for all other nucleosides analyzed in this study, fludarabine uptake was also partially dependent on the Na transmembrane gradient. A significant Na-dependent component of transport was found along with an equilibrative uptake which was mostly NBTI-sensitive and, thus, associated with ENT1 expression ( Figure 3B ). Since the major component of fludarabine uptake was equilibrative, apparent Km values for fludarabine transport into JVM-2 cells were derived from uptake measurements (data not shown) performed in choline chloride medium, either in the presence or in the absence of 1µM NBTI. Apparent Km for ENT1-mediated fludarabine transport was 82 µM. Thus, drug concentrations used are below the apparent Km. Vmax values ranged from 22 to 37 pmol/s/mg protein.
Nucleoside uptake into cells from CLL patients
Once the basal uptake measurement conditions had been established for natural nucleosides and for fludarabine, nucleoside transport activity was analyzed in CLL cells..
Since both cryopreserved and fresh samples have been used in this study, the putative effect of freezing and storing on nucleoside transporter performance was evaluated in randomly selected patients. Uptake rates were identical in fresh and cryopreserved CLL cells (not 
Ex vivo sensitivity to fludarabine and its relationship with fludarabine uptake
In 20 patients in vitro sensitivity of CLL cells to fludarabine was analyzed. As expected, incubation of cells with pharmacological doses of fludarabine (3 µM) and higher analysis, appear to play a significant role in resistance to cytarabine in AML patients. 23 As discussed above, this is not the case for CLL patients treated with fludarabine.
The extent to which mRNA levels of nucleoside transporter genes relate with their corresponding protein amounts and the latter with biological activity is unknown due to the lack of appropriate antibodies against the whole set of cloned human transporters.
Polyclonal monospecific antibodies against the rat isoforms of CNT1 and CNT2 have been generated in our laboratory. 15, 33 A lack of correlation between CNT1 mRNA levels and its corresponding protein amounts was initially found in rat liver. 33 Comprehensive CNT1 and CNT2 distribution analysis of rat tissues using Western blot also revealed this lack of correlation with CNT mRNA pattern distribution. 15 In rat cell and in vivo models of hepatocarcinogenesis it has been shown that nucleoside transporter expression can be lost selectively. 16, 17 More recently an antibody against human ENT1 has been characterized by others and used to monitor nucleoside transporter expression in breast cancer patients. 18 Although several ENT1 negative individuals were detected, this was not correlated with response to treatment or outcome. A polyclonal monospecific antibody against human only.
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CNT1 suitable for immunohistochemistry analysis in paraffin-embedded tissues has recently been raised and characterized in our laboratory. 34 Tissue array technology applied to gynecological tumors has revealed similar heterogeneous patterns in CNT1 expression (Farré, X., Guillén-Gómez, E., Sánchez, L., Casado, F.J., Palacios, J. , Pastor-Anglada, M., unpublished observations). To what extent protein levels will correlate with biological activity is also unclear, because nucleoside carrier proteins appear to be located also intracellularly 35 and post-translational modification of transporters has also been reported. 36 Intracellular trafficking defects may help to explain the lack of correlation between CNT2
and CNT3 mRNA levels with nucleoside uptake in CLL cells, but the lack of antibodies against these two human isoforms (not available commercially and not even reported in the literature) makes it difficult to address this point. But then, why do some CLL cells show Na-dependent transport activity but lack Na-dependent fludarabine accumulation?
Guanosine is a good substrate for both CNT2 37, 38 and CNT3 39 transporters, whereas fludarabine does not appear to be transported by the human isoform of CNT2, 40 ,although it is a substrate for CNT3. 39 .Thus, those cells showing concentrative guanosine uptake would express CNT2-but not CNT3-related transport activity. The high variability in CNT3 mRNA levels among patients along with negligible concentrative uptake of fludarabine, would be consistent with the idea that CNT3 is a highly inducible transporter. Moreover, its regulation from the gene to the active protein inserted at the plasma membrane would require a precise set of still unknown events in lymphoid cells, which are probably differentially altered in CLL cells. With the recent cloning of this isoform, it has been shown that CNT3 mRNA is present in HL60 cells at very low levels, but it is highly inducible (up to 17 fold) after cells are induced to differentiate. In summary, this study shows that cells from CLL patients express four nucleoside transporter genes, ENT1, ENT2, CNT2 and CNT3, with very different mRNA levels lacking any significant correlation with in vitro sensitivity to fludarabine treatment. This is probably due to the fact that nucleoside transport activity, directly measured in CLL cells, is mostly equilibrative (ENT related), although in some cases a CNT-2 concentrative Na-dependent transporter activity was found. Since fludarabine is not a CNT2 substrate, drug uptake is mediated by ENT transporters (mostly ENT1). In addition, ENT-mediated fludarabine transport significantly correlates with in vitro sensitivity to the drug. Therefore, we conclude that transporter-associated biological activity is a much more reliable predictive marker of therapeutic response to fludarabine in CLL patients than the quantitative analysis of transporter mRNAs. 
